Jennison Associates LLC raised its position in shares of Zoetis Inc (NYSE:ZTS) by 6.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,069,363 shares of the company’s stock after buying an additional 116,644 shares during the period. Jennison Associates LLC owned about 0.42% of Zoetis worth $110,442,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Interstate Bank boosted its stake in shares of Zoetis by 17.5% in the fourth quarter. First Interstate Bank now owns 2,174 shares of the company’s stock valued at $116,000 after buying an additional 324 shares in the last quarter. CENTRAL TRUST Co boosted its stake in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares in the last quarter. Huntington National Bank boosted its stake in shares of Zoetis by 15.7% in the first quarter. Huntington National Bank now owns 2,836 shares of the company’s stock valued at $151,000 after buying an additional 385 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Zoetis during the third quarter valued at $156,000. Finally, Foresters Asset Management Inc. boosted its stake in shares of Zoetis by 47.8% in the fourth quarter. Foresters Asset Management Inc. now owns 3,400 shares of the company’s stock valued at $182,000 after buying an additional 1,100 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.
Zoetis Inc (NYSE:ZTS) traded up 1.02% during trading on Friday, hitting $59.47. The stock had a trading volume of 6,896,027 shares. Zoetis Inc has a 52 week low of $45.28 and a 52 week high of $59.61. The company has a market cap of $29.26 billion, a price-to-earnings ratio of 36.04 and a beta of 1.07. The company has a 50-day moving average of $54.34 and a 200 day moving average of $52.87.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.48 by $0.05. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The business earned $1.23 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter last year, the firm posted $0.48 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. On average, equities research analysts anticipate that Zoetis Inc will post $2.32 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Thursday, April 6th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, April 4th. This represents a $0.42 annualized dividend and a yield of 0.71%. Zoetis’s dividend payout ratio is currently 30.44%.
Several analysts have weighed in on the company. BMO Capital Markets reissued a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Thursday. Zacks Investment Research raised Zoetis from a “sell” rating to a “hold” rating in a report on Friday, March 17th. Craig Hallum assumed coverage on Zoetis in a report on Wednesday, March 15th. They set a “buy” rating and a $65.00 price objective for the company. Guggenheim boosted their price objective on Zoetis from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 16th. Finally, Off Wall Street reissued a “strong sell” rating and set a $35.00 price objective on shares of Zoetis in a report on Thursday, February 16th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $57.12.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).